Sheep monoclonal antibodies prevent systemic effects of botulinum neurotoxin A1

Toxins

Volumn 4, Issue 12, 2012, Pages 1565-1581

  Mukherjee, Jean ^a   McCann, Chase ^a   Ofori, Kwasi ^a   Hill, Julia ^b   Baldwin, Karen ^a   Shoemaker, Charles B ^a   Harrison, Peter ^b   Tzipori, Saul ^a  

^a TUFTS UNIVERSITY   (United States)

^b Bioventix Ltd   (United Kingdom)

Author keywords

BoNT; BoNT A1; BoNT A2; Botulinum neurotoxin; Botulinum toxin; Botulism; Immunotherapy; Monoclonal antibodies; Passive immunization; Sheep monoclonal antibodies

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 16F9; MONOCLONAL ANTIBODY 1G4; MONOCLONAL ANTIBODY 2G11; MONOCLONAL ANTIBODY 4F7; MONOCLONAL ANTIBODY 5E2; MONOCLONAL ANTIBODY 5F7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY STRUCTURE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BOTULISM; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; INFECTION PREVENTION; LETHALITY; MOUSE; NEUROTOXICITY; NONHUMAN; PROVOCATION TEST; SHEEP; TOXIN STRUCTURE; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; BOTULINUM TOXINS, TYPE A; BOTULISM; FEMALE; IMMUNOGLOBULIN G; MICE; SHEEP; TREATMENT OUTCOME;

EID: 84873054885     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins4121565     Document Type: Article

References (22)

1. Middlebrook, J.L.; Franz, D.R. Botulinum toxins. In Medical Aspects of Chemical and Biological Warfare; Sidell, F.R., Takafuji, E.T., Franz, D.R., Eds.; Office of The Surgeon General at TMM Publications: Washington, DC, USA, 1997; pp. 643-651.
2. Simpson, L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 167-193.
3. Masuyer, G.; Thiyagarajan, N.; James, P.L.; Marks, P.M.; Chaddock, J.A.; Acharya, K.R. Crystal structure of a catalytically active, non-toxic endopeptidase derivative of clostridium botulinum toxin a. Biochem. Biophys. Res. Commun. 2009, 381, 50-53.
4. Meunier, F.A.; Schiavo, G.; Molgo, J. Botulinum neurotoxins: From paralysis to recovery of functional neuromuscular transmission. J. Physiol. Paris 2002, 96, 105-113.
5. Truong, D.D.; Stenner, A.; Reichel, G. Current clinical applications of botulinum toxin. Curr. Pharm. Des. 2009, 15, 3671-3680.
6. Osborne, S.L.; Latham, C.F.; Wen, P.J.; Cavaignac, S.; Fanning, J.; Foran, P.G.; Meunier, F.A. The janus faces of botulinum neurotoxin: Sensational medicine and deadly biological weapon. J. Neurosci. Res. 2007, 85, 1149-1158.
7. Cai, S.; Singh, B.R.; Sharma, S. Botulism diagnostics: From clinical symptoms to in vitro assays. Crit. Rev. Microbiol. 2007, 33, 109-125.
8. Baldwin, M.R.; Tepp, W.H.; Przedpelski, A.; Pier, C.L.; Bradshaw, M.; Johnson, E.A.; Barbieri, J.T. Subunit vaccine against the seven serotypes of botulism. Infect. Immun. 2008, 76, 1314-1318.
9. Arnon, S.S.; Schechter, R.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Fine, A.D.; Hauer, J.; Layton, M.; et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001, 285, 1059-1070.
10. Pless, D.D.; Torres, E.R.; Reinke, E.K.; Bavari, S. High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type a. Infect. Immun. 2001, 69, 570-574.
11. Amersdorfer, P.; Wong, C.; Chen, S.; Smith, T.; Deshpande, S.; Sheridan, R.; Finnern, R.; Marks, J.D. Molecular characterization of murine humoral immune response to botulinum neurotoxin type a binding domain as assessed by using phage antibody libraries. Infect. Immun. 1997, 65, 3743-3752.
12. Nowakowski, A.; Wang, C.; Powers, D.B.; Amersdorfer, P.; Smith, T.J.; Montgomery, V.A.; Sheridan, R.; Blake, R.; Smith, L.A.; Marks, J.D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 2002, 99, 11346-11350.
13. Cheng, L.W.; Stanker, L.H.; Henderson, T.D., 2nd; Lou, J.; Marks, J.D. Antibody protection against botulinum neurotoxin intoxication in mice. Infect. Immun. 2009, 77, 4305-4313.
14. Stanker, L.H.; Merrill, P.; Scotcher, M.C.; Cheng, L.W. Development and partial characterization of high-affinity monoclonal antibodies for botulinum toxin type a and their use in analysis of milk by sandwich elisa. J. Immunol. Methods 2008, 336, 1-8.
15. Binz, T.; Kurazono, H.; Wille, M.; Frevert, J.; Wernars, K.; Niemann, H. The complete sequence of botulinum neurotoxin type a and comparison with other clostridial neurotoxins. J. Biol. Chem. 1990, 265, 9153-9158.
16. LaPenotiere, H.F.; Clayton, M.A.; Middlebrook, J.L. Expression of a large, nontoxic fragment of botulinum neurotoxin serotype a and its use as an immunogen. Toxicon 1995, 33, 1383-1386.
17. Osborne, J.; Harrison, P.; Butcher, R.; Ebsworth, N.; Tan, K. Novel super-high affinity sheep monoclonal antibodies against cea bind colon and lung adenocarcinoma. Hybridoma 1999, 18, 183-191.
18. Coffino, P.; Laskov, R.; Scharff, M.D. Immunoglobulin production: Method for quantitatively detecting variant myeloma cells. Science 1970, 167, 186-188.
19. Bowmer, E.J. Preparation and assay of the international standards for clostridium botulinum type a, b, c, d and e antitoxins. Bull. Wld. Hlth. Org. 1963, 29, 701-709.
20. Hanna, P.A.; Jankovic, J. Mouse bioassay versus western blot assay for botulinum toxin antibodies: Correlation with clinical response. Neurology 1998, 50, 1624-1629.
21. Brown, D.R.; Lloyd, J.P.; Schmidt, J.J. Identification and characterization of a neutralizing monoclonal antibody against botulinum neurotoxin serotype f, following vaccination with active toxin. Hybridoma 1997, 16, 447-456.
22. Mullaney, B.P.; Pallavicini, M.G.; Marks, J.D. Epitope mapping of neutralizing botulinum neurotoxin a antibodies by phage display. Infect. Immun. 2001, 69, 6511-6514.